Bright Uro
Series A in 2024
Bright Uro is an early-stage medical technology company focused on developing innovative diagnostic devices for urology. The company has created a glean urodynamics system that combines advanced hardware, software, and data science to deliver wireless, catheter-free urodynamics. This system aims to enhance the accuracy and comfort of urological assessments, ultimately transforming the standard of care for patients with lower urinary tract symptoms and diseases. By providing actionable insights, Bright Uro empowers clinicians to improve patient outcomes and streamline the treatment process.
Neonc Technologies
Venture Round in 2024
NeOnc Technologies, Inc. is an early-stage cancer biotechnology company specializing in innovative delivery methods for a highly purified form of monoterpenes, derived from fruits and plants. The company focuses on intranasal inhalation and other nontraditional delivery techniques to enhance the treatment of malignant brain cancers, particularly gliomas, and plans to expand its applications to lung cancer in the future. Incorporated in Delaware in 2008, NeOnc has developed several proprietary molecules that have shown promising results in laboratory tests, contributing to a growing portfolio of intellectual property. Its lead product, NEO100, is currently in Phase 2a clinical trials for glioblastoma and has received Orphan Drug and Fast Track designations from the FDA. Additionally, NeOnc has established a partnership with a manufacturer for the development and production of its proprietary monoterpenes, further supporting its research and clinical initiatives.
Magnetic Insight
Grant in 2024
Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.
XLD operates a decentralized fintech platform aimed at providing financial services to emerging markets. The company focuses on modernizing financial delivery and infrastructure, ensuring that users have access to simple and reliable financial tools based on decentralized technology. By facilitating the use of cryptocurrency in everyday transactions, XLD enables clients to earn tokens and convert their crypto into fiat currency and other applications, fostering financial inclusion and accessibility.
ZiO Health
Non Equity Assistance in 2022
ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.
Dora Maar
Pre Seed Round in 2022
Dora Maar operates as an online retailer specializing in designer apparel and accessories for women. The platform focuses on offering a curated selection of pre-owned luxury fashion items, including dresses, tops, jackets, skirts, jumpsuits, bags, shoes, and various accessories. By connecting consumers with a network of influential tastemakers and consignors, Dora Maar allows customers to shop from the curated closets of those inspired by personal style and a thoughtful approach to fashion. This model not only promotes sustainable fashion practices but also enables customers to discover unique pieces that reflect contemporary trends.
Backer
Venture Round in 2021
Backer is a prominent fintech company specializing in 529 college savings plans, aimed at simplifying the process of saving for education. The company offers an investment platform that enables families to establish college savings plans efficiently, facilitating contributions from family and friends. Its user-friendly gifting platform and innovative mobile application enhance the experience by allowing for seamless tax-free investments. Backer's strategic partnerships with various 529 programs further bolster its high enrollment conversion rates, distinguishing it in the education savings market. The company's focus on making education savings accessible and straightforward supports families in planning for their children's educational futures.
Dora Maar
Pre Seed Round in 2021
Dora Maar operates as an online retailer specializing in designer apparel and accessories for women. The platform focuses on offering a curated selection of pre-owned luxury fashion items, including dresses, tops, jackets, skirts, jumpsuits, bags, shoes, and various accessories. By connecting consumers with a network of influential tastemakers and consignors, Dora Maar allows customers to shop from the curated closets of those inspired by personal style and a thoughtful approach to fashion. This model not only promotes sustainable fashion practices but also enables customers to discover unique pieces that reflect contemporary trends.
nFlux AI
Pre Seed Round in 2020
nFlux AI is a developer of an artificial general intelligence platform focused on enhancing human capabilities through advanced technology. The company specializes in computer vision operations, providing intelligent video analytics that automate the extraction of contextual insights from unstructured data within video footage. This innovative approach allows clients to leverage proprietary machine comprehension services, enabling a deeper understanding of their data. nFlux's first significant collaboration was with NASA, where the company was tasked with creating a cognitive architecture to support deep space missions, allowing intelligent systems to assist astronauts autonomously when communication with Earth is not feasible. The company's vision is to advance intelligence in ways that positively impact humanity, supported by investments from prominent organizations and venture capital firms.
The SpringHill Company
Venture Round in 2020
The SpringHill Company LLC, based in Los Angeles, California, was established in 2020 and specializes in brand development and management services. It operates through three main divisions: SpringHill Entertainment, Uninterrupted, and The Robot Company. The company focuses on producing a variety of media content, including feature films, television series, web series, and short films. In addition to content creation, The SpringHill Company offers consultancy services to media partners, helping them craft compelling stories for various platforms including television and digital networks. The company also engages in event management services, enhancing its portfolio in the media and entertainment industry.
ArsenalBio
Series A in 2019
ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.
sensfix
Convertible Note in 2019
Sensfix B.V., founded in 2018 and based in Amsterdam, develops a technology-agnostic platform designed for asset management across various infrastructure applications, such as streetlights, buildings, bank ATMs, and city gas systems. Its IoT-connected platform allows machines to autonomously schedule and manage their repair and maintenance needs while ensuring transparent decision-making among all stakeholders. By digitizing workflows and implementing a machine-initiated real-time ticketing system, Sensfix aims to enhance the efficiency of operations. The platform leverages IoT sensors to facilitate instantaneous connections between assets, owners, and service personnel, enabling self-scheduling, self-dispatch, and self-ticketing services. This enterprise SaaS solution is reported to reduce the operational and maintenance costs of physical assets by 30% and achieve a repair success rate on the first visit while minimizing repair failures to less than 1%.
Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.
Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.
Licious is an innovative company in the Indian food industry focused on addressing the ongoing challenge of providing safe and high-quality fresh meat. It operates an online meat delivery platform that offers a variety of meat products, including fresh chicken, lamb, and seafood. Licious ensures that its products are carefully procured, processed, and stored, allowing consumers to conveniently receive fresh meat delivered directly to their homes. By enhancing the procurement and consumption of meat in India, Licious aims to transform the way meat is sourced and enjoyed by consumers across the country.
DNALite Therapeutics
Seed Round in 2018
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.
BetterPet
Seed Round in 2014
BetterPet, Inc. was established with one mission in mind: Improve the lives of pets and their owners everywhere. With the rise of mobile phones, tablets, and a vast array of ever-evolving digital technologies, why should we humans have all the fun? We create products that strengthen the bond between people and their pets and that connect the community of animal lovers worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.